The Dietary Inflammatory Index and Chronic Lymphocytic Leukaemia in the MCC Spain Study

José Carlos Flores1, Esther Gracia-Lavedan1,2,3, Yolanda Benavente2,4

  • 1Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08002, Spain.

Nutrients
|December 28, 2019
PubMed

Insights

Dietary inflammation, assessed by the dietary inflammatory index (DII®), was not significantly linked to chronic lymphocytic leukemia (CLL) risk in this Spanish study. Further research on pro-inflammatory diets in younger populations is warranted.

Area of Science:

  • Epidemiology
  • Nutrition Science
  • Oncology

Background:

  • Chronic inflammation is implicated in chronic lymphocytic leukemia (CLL) development.
  • Dietary patterns may influence chronic inflammation levels.
  • Understanding diet-CLL associations is crucial for prevention strategies.

Purpose of the Study:

  • To investigate the association between the dietary inflammatory index (DII®) and the risk of chronic lymphocytic leukemia (CLL).

Main Methods:

  • A multicase-control study in Spain included 366 CLL cases and 1643 controls.
  • Dietary inflammatory potential was assessed using the energy-adjusted dietary inflammatory index (E-DII).
  • Logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI), controlling for confounders.

Main Results:

  • A modest, non-statistically significant, positive association was observed between higher E-DII scores and CLL risk (OR for one-unit increase: 1.05; 95% CI: 0.99–1.12; p=0.09).
  • No significant association was found when analyzing E-DII by tertiles (p trend=0.21).
  • Results remained consistent regardless of disease severity, time from diagnosis, or treatment status.

Conclusions:

  • The consumption of a pro-inflammatory diet was not significantly associated with chronic lymphocytic leukemia (CLL) risk in the studied population.
  • Future research should explore the impact of pro-inflammatory dietary patterns on younger generations and CLL development.